Bispecific CD19-directed CD3-directed T Cell Engager



Blinatumomab Injection

blinatumomab 0.035 MG InjectionGeneric
blinatumomab 0.035 MG Injection [Blincyto]Generic

Blinatumomab drug classes:

  • Bispecific CD19-directed CD3-directed T Cell Engager

Blinatumomab pharmacologic actions:

  • Antineoplastic Agents

Blinatumomab mechanism of action:

  • CD3 Receptor Agonists
  • CD19-directed Antibody Interactions
  • CD3-directed Antibody Interactions
  • treatable

The content offered on is intended for informational purposes only and not as medical advice. For medical advice you should consult an appropriately licensed and qualified medical professional. If you are experiencing acute or distressing symptoms or life threatening symptoms you should immediately call 911 and/or go to the nearest emergency medical facility.

LegitScript approved
Copyright © Treatable 2023
Last updated: 2/2/2024, 6:50:57 PM